MRNA VACCINE RISKS
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are underway for lung, bladder, kidney, pancreatic, and stomach cancers.
Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trial
Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are expected within the next few months.
mRNA vaccines protect against severe infectious diseases, review confirms
Billions of mRNA vaccine doses administered globally confirm their safety and effectiveness against infectious diseases, including severe COVID-19, across all age groups and health conditions. Researchers emphasize that serious side effects are rare, with benefits far outweighing risks. This technology, now proven, holds immense promise for future vaccines and personalized treatments, though equitable global access remains crucial.
As Covid cases rise in US, RKF Jr sparks uproar as he cancels half-billion dollar in funding for mRNA vaccines
The US Department of Health and Human Services has planned to cancel $500 million in funding for mRNA vaccines, citing potential risks and limited effectiveness against respiratory viruses. HHS Secretary Robert F. Kennedy Jr. stated the department will shift focus towards safer, broader vaccine platforms. This comes at a time as Covid cases are seeing a surge in the US.
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
The FDA has issued warnings regarding potential cardiac risks, specifically myocarditis and pericarditis, associated with the Pfizer and Moderna COVID-19 vaccines. These risks are particularly elevated in young men, prompting the FDA to update vaccine labels with clearer information. While the FDA continues to monitor vaccine safety and supports their use, ongoing studies are assessing long-term heart effects.
- Go To Page 1
Research finds risk of developing 'extremely rare' Guillain-Barre syndrome increases due to Covid
New research from medical institutes in Israel has found that individuals who have been infected with Covid-19 are at an increased risk of developing Guillain-Barre syndrome in the six weeks following the infection.
Pfizer bivalent vaccine reduces Covid-related death risk by 68% in older people: Study
5,69,519 eligible participants were identified between September 27, 2022, and January 25, 2023. Of those, 1,34,215 (24 per cent) participants received a bivalent mRNA booster vaccination during the study period. Hospitalisation due to COVID-19 occurred in 32 participants who received a bivalent mRNA booster vaccination and 541 who did not receive a bivalent booster vaccination. Analysis showed this to mean a 72 per cent reduction in hospitalisation risk in those receiving the bivalent booster.
Cancer vaccines are being developed using tech similar to that used for Covid shots
Decades before Covid vaccines, scientists had been working on messenger ribonucleic acid (mRNA) vaccines targeting cancer.
mRNA technology-based Cancer vaccine boosts chances of survival: Moderna
Data revealed that using Merck's immunotherapy drug in combination with high-risk patients decreased their risk of dying.
COVID-19 mRNA vaccines increase risk of cardiac-related death, says Florida Surgeon General
The Florida Department of Health (Department) conducted an analysis through a self-controlled case series, which is a technique originally developed to evaluate vaccine safety. This studied mortality risk following mRNA COVID-19 vaccination.
NTAGI could decide on mRNA vaccine's inclusion in national drive next week
India's drug regulator approved Gennova's mRNA vaccine for restricted use in emergency situations in adults early this week.
FDA flags heart issues after taking Novavax vaccine
In the company's nearly 30,000 patient trial, conducted between December 2020 and September 2021, there were four cases of myocarditis, a type of heart inflammation also associated with mRNA vaccines, detected within 20 days post vaccination.
Some short-term benefit of additional booster dose of mRNA vaccine in health workers: WHO
The WHO cited seven studies, conducted during a time when Omicron was the predominant circulating strain globally, that evaluated the relative effectiveness of a fourth dose four months after a third dose of mRNA vaccine compared to those who received three doses.
Covid raises risk of heart problems more than vaccine: CDC
These findings, which were for both males and females in all age groups, supported the continued use of recommended mRNA Covid-19 vaccines among all eligible persons aged over 5 years, the CDC said in its latest weekly Morbidity and Mortality Weekly Report.
Moderna COVID-19 shot more likely to cause heart inflammation than Pfizer's, study shows
Moderna's COVID-19 vaccine is up to four times more likely to cause inflammation of the heart muscle, a very rare side effect, than its rival vaccine from Pfizer-BioNTech , according to a Danish study published in the British Medical Journal late on Thursday.
Gennova to finish Phase 2 & 3 trials of its mRNA jab by January 2022
The company had submitted the interim Phase-1 clinical trial data to CDSCO, where it tested for safety and immunogenicity.
Experimental mRNA vaccine for HIV shows promise in animals
The research, which was carried out by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), Moderna and other institutions, demonstrated that the vaccine was safe and prompted desired antibody and cellular immune responses against an HIV-like virus.
Combining AstraZeneca vaccine with mRNA jab highly effective against COVID-19, shows Lancet study
The study showed a 67% lower risk of infection for the combination of AstraZeneca and Pfizer vaccine shots.
Mix-and-match vaccines highly effective against COVID-19: Lancet study
Since the use of AstraZeneca's vector-based vaccine against COVID-19 was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose.
No sign of Pfizer, Moderna Covid vaccines in breast milk: Study
The study, published in the journal JAMA Pediatrics, offers the first direct data of vaccine safety during breastfeeding and could allay concerns among those who have declined vaccination or discontinued breastfeeding due to concern that vaccination might alter human milk.
Pfizer, Moderna vaccines cut COVID-19 risk by 91 per cent: Study
The research, published in the New England Journal of Medicine on June 30, is among the first to show the benefits of mRNA vaccines even among those who experience breakthrough infections -- testing positive after immunisation.
AstraZeneca shots should be halted for over-60s too: EMA official
The European Medicines Agency (EMA) considers the Astrazeneca shot safe for all age groups. However several European Union member states have stopped administering it to people below a certain age, usually ranging from 50 to 65, restricting its use to the older population, due to the rare cases of blood clotting, mainly among young people.
Get Pfizer in, work out indemnity
WHO experts opine there could be one or more Indian variants of the SARS Cov-2 virus that escape available vaccines.
Pfizer, Moderna vaccines 'don't appear to pose serious risk' during pregnancy, says new study
CNN reported that pregnant women with COVID-19 are at increased risk for severe illness and may be at increased risk for adverse outcomes, such as preterm birth, according to the US Centers for Disease Control and Prevention.
HGCO19 vaccine candidate: Gennova starts enrolment for Phase 1/2 human clinical trials
The DBT said it has approved additional funding towards clinical studies of India's first of its kind' mRNA-based COVID-19 vaccine, HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.
Pfizer, Moderna COVID-19 vaccines highly effective even after first shot in real-world use
The study by the U.S. Centers for Disease Control and Prevention (CDC) evaluated the vaccines' ability to protect against infection, including infections that did not cause symptoms. Previous clinical trials by the companies evaluated their vaccine's efficacy in preventing illness from COVID-19.
Pfizer, Moderna vaccines may greatly reduce risk of asymptomatic COVID-19 infection, study says
The Pfizer-BioNTech and Moderna messenger RNA (mRNA) vaccines for COVID-19 are authorised for emergency use in many countries. An mRNA vaccine is based on the segments of the genetic material, or RNA, of the novel coronavirus.
China starts work on plant for mRNA-based COVID-19 vaccine candidate: Media
The mRNA technology contains instructions for human cells to make proteins that mimic part of the coronavirus, and is used in vaccines from Moderna Inc as well as from Pfizer Inc and BioNTech SE.
Load More
